Summary Many tumours express relatively high levels of low-density lipoprotein (LDL) receptors on their membranes. The LDL receptor is, therefore, an attractive target for the selective delivery of antineoplastic drugs to tumour cells. We reported previously on the synthesis of small apolipoprotein E (apoE)-containing liposomes that behave in vivo in a very similar way to native LDL. In this study, we (LAD). Tissue distribution studies showed that LAD-loaded apoE liposomes were taken up and processed by the major LDL receptor-expressing organs (i.e. adrenals, liver and spleen). Of all other tissues, the tumour showed the highest uptake. The distribution pattems of LAD-loaded apoE liposomes and native LDL in the tumour-bearing mice were very similar, which supports the role of the LDL receptor in the disposition of the prodrug-loaded particles. The disposition of LAD followed the pattem of the liposomal carrier. We conclude that apoE liposomes enable LDL receptor-mediated specific delivery of antineoplastic (pro) 
Because of their rapid proliferation. tumour cells require large amounts of cholesterol for the svnthesis of membranes. A varnetx of tumour cells fulfil their need for cholesterol bv an increased receptor-mediated uptake of the low-density lipoprotein (LDL).
For instance. malignant blood cells implicated in acute mveloid leukaemia intemalize 3-100 times more LDL than normal cells (Ho et al. 1978) . In addition. tumours in brain. lung. colon. kidney and tumours of grnaecological origin have been sho%% n to express high levels of LDL receptors (Firestone. 1994 (Mosley reported. Masquelier et al (1986) and Samadi-Baboli et al (1993) showed that the LDL in drug-LDL complexes wvas cleared normally. We examined earlier the in vivo fate of both the druc and LDL in complexes that had been prepared by 'arious established incorporation procedures (De Smidt and Van Berkel. 1990 ). These complexes displayed LDL receptor-mediated uptake by cultured cells. Howexer. we found that in vio the druc rapidly dissociated from LDL. or that the complexes were taken up by mechanisms independent of the LDL receptor. Probably. incorporation of drugs into LDL causes subtle modifications in the structure of apoB. which modifies the in vivo behaviour of LDL. Thus. the construction of a drug-LDL complex that has a satisfactorv in vivo behaviour constitutes a major problem for the application of LDL receptor-mediated uptake. In addition. the limited axailability of native LDL is a pharmaceutical limitation. The preparation of LDL-resembling lipid particles from commercially available lipids w ould facilitate a large-scale production. These particles. how-ever. do need a specific marker to ensure LDL-receptor recognition. As it is difficult to associate delipidated apoB (514 kDa) with lipid particles in its correct tertiary structure Suominen. 1984: Lundberg et al. 1993) . we explored the possibility of using apolipoprotein E as a recognition marker. The 34-kDa glcoprotein apolipoprotein E (apoE). present on triglyceride-rich lipoproteins like chy lomicrons and very low-densitv lipoprotein. represents a good alternative for apoB. It is a high-affinity ligand for the LDL receptor. if associated with lipid particles Mahley. 1978: Innerarity et al. 1979) . The affinity of particles exposing minimally four copies of apoE on their surface for the LDL receptor is even 15-to 25-fold higher than that of native LDL. which is probably due to multivalent receptor binding (Pitas et al. . 1980 ). An additional advantage of apoE is that it can be produced by recombinant DNA technology.
We combined the advantages of a synthetic lipid particle (largescale production) with those of recombinant apoE (as high-affinity ligand for the LDL receptor) to construct a carrier suitable for the specific delivery of drugs to tumours. Small liposomes (approximate size 29 nm) were prepared. which were provided with 5 or 6 apoE molecules per particle (Rensen et al. 1997 ). These liposomes were found to be stable in the circulation. Further. LDL receptormediated uptake was demonstrated in vivo in rats with a chemically induced (by 17a-ethinyl oestradiol pretreatment) high-LDL receptor expression on the liver. Uptake by the reticuloendothehal system was negligible (Rensen et al. 1997) . A lipophilic antineoplastic prodrug was synthesized. and incorporated in the liposomes (Versluis et al. 1998 ). The prodrug. denoted LAD ( Figure  1) . consists of the anthracycline daunorubicin. which is coupled via a lysosomally degradable tetrapeptide spacer (alanylleucyl-alanyl-leucyl) to a cholesteryl oleate analogue [3cx-0-
The aim of the present study was to investigate the tumourlocalizing properties of (LAD-loaded) apoE-enriched liposomes.
The B 16 tumour-mouse model was used because the LDL receptor expression on B16 cells has been well characterized (Ponty et al. 1993 : Versluis et al. 1996 . We investigated the LDL receptor-mediated interaction of apoE-enriched liposomes with cultured B16 tumour cells. and evaluated the disposition of the liposomal carrier and the liposome-associated prodrug in the tumour tissue in vivo.
MATERIALS AND METHODS

Chemicals
Recombinant human apolipoprotein El (apoE) . isolated from Escherichia coli. was a generous gift from Dr T Vogel.
Biotechnology General. Rehovot Israel (Vogel et al. 1985) . ApoE was dissolved in phosphate-buffered saline (PBS: 10 lrOm sodium phosphate buffer. pH 7.4. containing 0.15 M sodium chloride) at a concentration of 2 mg, ml-'. and was stored under argon at -00C. Preparation and apoE enrichment of (LAD)liposomes Liposomes were prepared by sonication using a procedure described previously by Rensen et al (1997) . In short. EYPC and CO (52 mg of total lipid at a ratio of 25:1) were hydrated in 1 1. ['4C ]CO (for the tissue distribution experiments). After sonication. the liposomes were purified and concentrated by density-gradient ultracentrifugation at 285 000 g for 18 h at 4°C. according to Redgrave et al (1975) . After centrifugation. the liposomes. visible as a narrow opalescent layer at approximately three-quarters of the tube height. were isolated by aspiration. When indicated. liposomes were subsequently incubated with apoE. at an apoE:phospholipid ratio of 1:10 (w/w). After 30 min at 37°C. the incubation mixture was subjected to density-gradient ultracentrifugation as described above. and apoE-containing liposomes were subsequently isolated by aspiration. Finally, the (apoE) liposomes were dialysed against PBS containing 1 ntm EDTA. Liposomes were stored at 200C under argon and used within 7 days after preparation. in which period no physicochemical changes could be detected.
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Characterization of lipsomes
The EYPC and CO contents of the purified liposomes were determined using enzymatic kits for phosphatidylcholine and esterified cholesterol (Boehringer Mannheim, Mannheim, Germany) respectively. Precipath L was used as standard. The incorporation of [3H]LAD was assayed by measuring its radioactivity as described below. Particle size and homogeneity were determined by photon correlation spectroscopy at a temperature of 270C, using a Malvem 4700c submicron particle analyser set at an angle of 900 between laser and detector (Malvern Instruments, Malvern, Worcestershire, UK).
Isolation and radioiodination of LDL
Human LDL (density 1.024-1.063 g ml-') was isolated from the serum of healthy fasted volunteers by density-gradient ultrwentrifugation according to Redgrave et al (1975) . The LDL solution was subsequently dialysed against PBS containing 1 mM EDTA, and was sterilized by filtration through a 0.22-jim filter (Millipore, Molsheim, France). The concentration of the LDL solution was determined by measuring apoB, according to the method of Lowry et al (1951) with bovine serum albumin (BSA) as standard. For in vitro experiments, LDL was labelled using the ['5l ]iodine monochloride method as described in detail by Bilheimer et al (1972) . For in vivo experiments, LDL was labelled with '1I-tyrammne cellobiose ('-I-TC) as described previously (Versluis et al, 1996) .
The specific radioactivity of radiolabelled LDL was 50-200 d.p.m. ng-' of apolipoprotein and less than 1% of the labelled material was soluble in trichloroacetic acid.
Cufture of B16 Melanoma cells and of cells for experiments
The B16 (wild type) melanma cell line was cultured at 37°C in a humidified 5% carbon dioxide/air atmosphere in 500-cm2 flasks (Costar), contining 20 ml of DMEM supplemented with 10% (v/v) heat-iactivated fetal calf serum. 2 mM L-glutamme, 50 IU ml' penicilin and 50 jg mL-streptomycu Cells were sbcured twice a week by detahiing the cells with ntypsin (0.25% solutio in Ca2-and mg-depieted Hanks' buffer), followed by renewal of medium the next day. Protein content per cell number was determined according to the nmetod of Lowry et al (1951) with BSA as sandard.
To perform experiments, B16 cells were plated in 22-mm-diameter 12-well culture plates at a density of 20 000-40 000 cells per well. Experiments were carried out 2 or 3 days later with subconfluently grown cells. Before the experiments, the culture medium was replaced by preincubation medium [medium with 1% (w/v) BSA instead of fetal calf serum]. The cells were washed three times with preincubation medium (for 10. 10 and 30 min), and then cultured in this medium for a further 18 h. Experiments (see below) were started, after two quick washes with preincubation medium, by the addition of preincubation medium containing radiolabelled ligands, either alone or with the indicated additions.
Binding of radioabelled apoE liposomes and LDL by B16 cells in culture
To determine the binding of radiolabelled apoE liposomes and LDL to B 16 cells, the cells were incubated with increasing concentrations of the radiolabelled ligand for 3 h at 4°C. After incubation, the culture plates were placed on ice. The cells were washed five times with ice-cold wash buffer (0.15 M sodium chloride, 2.5 mM calcium chloride and 50 mM tris-HCI, pH 7.4) containing 0.2% (w/v) BSA, followed by two washes with the same buffer without BSA. The cells were then lysed with 1 ml of 0.1 N sodium hydroxide and the amounts of protein and radioactivity in the lysate were determined. The amount of cell protein was determined by the method of Lowry et al (1951) with BSA as standard.
Association and degradation of radiolabelled apoE liposomes and LDL by B16 cells in culture
To determine association and degradation of radiolabelled apoE liposomes and LDL by B 16 cells, the cells were incubated with the radiolabelled ligands and the indicated additives for 3 h at 370C. After the incubation, the culture plates were placed on ice. To determine degradation of ['5l ]LDL, 0.5 ml of the incubation medium was taken from the cells, and the amounts of released degradation products of ['2l51LDL were determined as described previously by Van Berkel et al (1981) . The cell-associated radioactivity was determined as described above for cell-bound radioactivity.
Detemination of in vivo fate of (LAD-loaded) apoEcontaining liposomes and LDL Male C57/BL6 mice (10-15 weeks old) were used. The animals were kept in compliance with the guidelines issued by the Dutch authorities. The mice were fed with normal chow and had free access to water. Mice were inoculated subcutaneously. both on the left and the right flank of their back with 2.5 x 10-1 B16 cells obtained from cell culture (inoculation was performed under diethyl ether anaesthesia). After the development of small (<0.1 g) tumours, the mice received an intravenous injection of radiolabelled (LAD-loaded) apoE-containing liposomes. At 2, 4 or 8 h after injection, the mice were anaesthetized with diethyl ether, and a 0.4 ml blood sample was taken. The mice were subsequently Britsh Journal of Cancer (1998) 78(12) , [1607] [1608] [1609] [1610] [1611] [1612] [1613] [1614] (Versluis et al, 1996) . Figure 3A and B, and the effects on the degradation of ['12 ]LDL by the cells are depicted in Figure 3C and D. To examine the role of apoE, both apoE-containing liposomes and liposomes devoid of apoE were used Both LDL and the liposomes were able to inhibit British Jo/rnal of Cancer (1998) LDLr-mediated drug delivery to B 16 tumour by apoE liposomes 1611 Ca' dependent (Goldstein and Brown. 1974 ). We showed recentlI that the interaction of LDL with B 16 cells is also strongly Ca'+ dependent (Versluis et al. 1996) . Percentage of injected dose g-' Figure 6 Tissue distribution of LAD-loaded apoE-liposomes. liposomes by the organs and the tissues shows a striking similarity with that of LDL. which strongly suggests the involvement of the LDL receptor in the uptake of LAD-loaded apoE-enriched liposomes.
DISCUSSION
We recently synthesized small apoE-containing liposomes. with the aim of using these particles for the selective delivery of antineoplastic agents to tumours via the LDL receptor. The apoE liposomes behaved in vivo similarly to native LDL (i.e. no significant uptake by the reticuloendothelial system and metabolic fate dependent on the level of LDL-receptor expression: Rensen et al. 1997 ). We fther incorporated LAD. a lipophilic prodrug, of daunorubicin. into these liposomes (approximately ten prodrug molecules per particle: Versluis et al. 1998) . In the present study. we investigated the interaction of apoE-containing liposomes with cultured B16 melanoma cells, and we studied the tumour-localizing properties of LADloaded apoE-liposomes in the B 16 tumour-mouse model. Brown. 1974) . The essential role of apoE for the recognition of the liposomes by the LDL receptor became evident from the finding that liposomes lacking apoE are far less effective in competing for receptor binding. ApoE liposomes bind to the LDL receptor with a 15-fold higher affinity (Kd 0.77 nM) than LDL (Kd 11.5 nm). The number of binding sites for apoE liposomes is. however, two-to 2.5-fold lower than that for LDL (90 000 versus 220 000). These results are in agreement with the findings of Pitas et al (1980) . who showed that lipid vesicles provided with increasing numbers of apoE molecules displayed an increasing affinity for the LDL receptor. The maximum affinity. which was 25-fold higher than that of LDL. was reached when at least four apoE molecules were present per particle. At this point. the maximal binding capacity was decreased fourfold. indicating multivalent binding of the apoE-containing particles to LDL receptors.
The tumour-localizing properties of the apoE liposomes were studied by administering LAD-loaded apoE-liposomes to B 16 tumour-bearing mice. To study processing. the liposomes were double-labelled with a non-degradable lipid label (represents total amount taken up) and a biodegradable label. The latter can be metabolized and excreted. and gives an indication of the processing of the particles. We found that the particles are not processed in the circulation, but were taken up and rapidly processed by the three organs with a high expression of the LDL receptor (i.e. liver. adrenals and spleen). Thus. the prodrug-loaded liposomes are. like native LDL. intemalized and processed. Of all other organs. the tumour showed the highest uptake. However. we detected no significant difference in accumulation of the labels in the tumour. This finding does not necessarily mean that the liposomes are not processed by the tumour. The liver and adrenals use cholesterol for the synthesis of secretion products (bile salts. corticosteroid hormones). Tumours. however. use the cholesterol to synthesize cellular components that remain cell-associated. Further. earlier results indicate that LDL is processed by the B 16 tumour inoculated in mice. albeit at a somewhat lower rate than in liver and adrenals (Versluis et al. 1996) . The tissue distribution of LAD-loaded apoE-liposomes is very similar to that of native LDL. which further supports the involvement of the LDL receptor in the uptake of LAD-loaded apoE liposomes.
The ability of the apoE liposomes to deliver LAD to the tumour was studied by injecting [3H]LAD-loaded apoE liposomes. The serum clearance of the radiolabelled prodrug was similar to the serum clearance of the radioactivity after injection of LAD-loaded [3H]CO-labelled apoE liposomes. indicating a concomitant clearance and uptake of drug and carrier. The recovery of LAD in the tissues was much lower than that of the non-degradable liposomal label. which points to processing of the prodrug. This suggests that. as anticipated. daunorubicin is released from the tetrapeptide spacer and is further metabolized. Assuming that all incorporated LAD is delivered to the tumour. and that tumour cells constitute 10% of the tumour weight (Murray and Carmichael. 1995) . it can be calculated that approximately 0.2 tmol of LAD can be delivered per litre of B16 cell volume at the present dosing. The effective intracellular anthracycline concentration. which is in the JiM range (Speth et al. 1988) . should easily be reached by higher and more frequent dosing.
Uptake of the prodrug-loaded liposomes by liver. spleen and adrenals is higher than the uptake by the tumour. If a therapeutic dose is to be targeted to the tumour. precautions are necessary to protect these organs from irreversible tissue damage. Expression of LDL receptors in the liver can be decreased by a diet enriched in cholesterol and triglycerides rich in saturated fatty acids (Angelin et al. 1983 : Dietschy et al. 1993 : Packard et al. 1983 ). The expression of LDL receptors in the spleen and adrenals can be significantly reduced by the administration of bile salts and corticosteroids respectively (Hynds et al, 1984 : Isaacsohn et al. 1986 ).
In conclusion. apoE liposomes. prepared from commercially available lipids and recombinant apoE. can be used as carriers for LDL receptor-mediated delivery of drugs to tumours. The particles have a much higher affinity for the LDL receptor than native LDL. which affords a competitive advantage. The liposomes have the capacity to incorporate lipophilic anti-tumour (pro)drugs in the phospholipid bilayer and water-soluble drugs in the aqueous core. which provides numerous possibilities to further develop the drugdisposing properties of the apoE-enriched liposomes. ApoEenriched liposomes are. thus. a new option and stimulus for the application of a LDL receptor-mediated tumour therapy.
